Yankees Score with ...
Health Care: Drugs
Merck & Co Inc (MRK: NYSE)
$47.16 -0.17 | -0.36%
05/24/13 - 04:00 PM ET
Company Balance Sheet
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 13.45B | 13.53B | 10.90B | 9.31B |
| Receivables | 7.67B | 8.26B | 7.34B | 6.60B |
| Inventories | 6.54B | 6.25B | 5.87B | 8.06B |
| Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Assets | 34.86B | 33.18B | 29.06B | 28.43B |
| Property, Plant & Equipment, Gross | 33.42B | 32.47B | 30.56B | 30.87B |
| Accumulated Depreciation & Depletion | 17.38B | 16.18B | 13.48B | 12.59B |
| Property, Plant & Equipment, Net | 16.03B | 16.30B | 17.08B | 18.27B |
| Intangibles | 29.08B | 34.30B | 39.46B | 47.66B |
| Other Non-Current Assets | 14.03B | 9.19B | 7.80B | 5.81B |
| Total Non-Current Assets | 71.28B | 71.95B | 76.72B | 83.66B |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 106.13B | 105.13B | 105.78B | 112.09B |
| Accounts Payable | 1.75B | 2.46B | 2.31B | 2.24B |
| Short Term Debt | 4.32B | 1.99B | 2.40B | 1.38B |
| Other Current Liabilities | 2.54B | 2.06B | 2.42B | 2.68B |
| Total Current Liabilities | 18.35B | 16.24B | 15.64B | 15.75B |
| Long Term Debt | 16.25B | 15.52B | 15.48B | 16.07B |
| Deferred Income Taxes | 16.07B | 16.42B | 17.85B | 18.77B |
| Other Non-Current Liabilities | 0.00 | 0.00 | 0.00 | 0.00 |
| Minority Interest | 131.00M | 120.00M | 121.00M | 122.90M |
| Total Non-Current Liabilities | 34.76B | 34.37B | 35.76B | 37.28B |
| Total Liabilities | 53.11B | 50.61B | 51.40B | 53.03B |
| Preferred Stock Equity | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Stock Equity | 53.02B | 54.52B | 54.38B | 59.06B |
| Common Par | 1.79B | 1.79B | 1.79B | 1.78B |
| Additional Paid In Capital | 40.65B | 40.66B | 40.70B | 39.68B |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | 39.98B | 38.99B | 37.54B | 41.40B |
| Treasury Stock | -24.72B | -23.79B | -22.43B | -21.04B |
| Other Equity Adjustments | -4.68B | -3.13B | -3.22B | -2.77B |
| Total Capitalization | 69.27B | 70.04B | 69.86B | 75.13B |
| Total Equity | 53.02B | 54.52B | 54.38B | 59.06B |
| Total Liabilities & Stock Equity | 106.13B | 105.13B | 105.78B | 112.09B |
| Total Common Shares Outstanding | 3.03B | 3.04B | 3.08B | 3.11B |
| Preferred Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Treasury Shares | 1.10B | 536.11M | 494.84M | 454.31M |
| Basic Weighted Shares Outstanding | 3.04B | 3.07B | 3.10B | 2.27B |
| Diluted Weighted Shares Outstanding | 3.08B | 3.09B | 3.12B | 2.27B |
| Number of Employees | 83000 | 86000 | 94000 | 100000 |
| Number of Part-Time Employees | 0 | 0 | 0 | 0 |
Portfolios with MRK
- Portfolio NameUser Type
- Userralphd2
- User2013
- ContributorStocks Rising On Unusual Vo...
- UserJeeper Portfolio 1
- UserCapt Jer
- Userlennyvb Portfolio 1
- ContributorDogs of the Dow 2013
- ContributorTechnical Setups for the We...
- ContributorHigh Volume Technicals for ...
- UserCovered Calls
Latest MRK Headlines from TheStreet
- Cramer's 'Mad Money' Recap: Haves and Have-Nots 04.17.13 | 08:04 pm
- Cramer Talks Abbott & Glaxo
04.17.13 | 03:04 pm - March Into Merck, Aflac and Nordstrom Shares 04.17.13 | 02:04 pm
- 'Mad Money' Uncovered: Big Pharma on a Down Day in the Market 04.15.13 | 01:04 pm
- Mad Money Uncovered: Merck and the Pharma Laggards 04.15.13 | 12:04 pm
- Merck & Co Inc Stock Buy Recommendation Reiterated (MRK) 04.15.13 | 10:04 am
- Cramer's 'Mad Money' Recap: The Bulls Are In Charge 04.10.13 | 08:04 pm
- Merck & Co Inc (MRK): Health Care's Featured Stock Of The Day 04.10.13 | 05:04 pm
- Cramer's Top Stock Picks: MKC MRK PCLN EXPE TJX 04.10.13 | 06:04 am
- Cramer's 'Mad Money' Recap: As China Goes... 04.09.13 | 08:04 pm
Press Releases for MRK
- Pharmaceutical Companies, Investor Coalition Develop Industry Standard-Setting Principles For Recoupment Policies Covering Major Compliance Failures - PR Newswire 04.04.13 | 08:04 am
- Merck Announces FDA Acceptance Of Biologics License Application For Investigational Grass Pollen Allergy Immunotherapy Tablet - Business Wire 03.27.13 | 08:03 am
- Merck And Luminex Corporation Enter Agreement To Develop Companion Diagnostic To Support Investigational BACE Inhibitor Clinical Development Program For Alzheimer’s Disease - Business Wire 03.13.13 | 08:03 am
- Results From HPS2-THRIVE Study Of TREDAPTIVE™ (extended-release Niacin/laropiprant) Presented At American College Of Cardiology Scientific Sessions - Business Wire 03.09.13 | 12:03 pm
- Roger M. Perlmutter (Photo: Business Wire) - Business Wire 03.07.13 | 07:03 am
- Merck To Present At The 33rd Annual Cowen Health Care Conference - Business Wire 03.05.13 | 08:03 am
- Merck Announces Second-Quarter 2013 Dividend - Business Wire 02.26.13 | 02:02 pm
- Merck To Present At The Citi 2013 Global Healthcare Conference - Business Wire 02.26.13 | 08:02 am
- Merck To Present New Data Analyses Of Its Investigational Ragweed Pollen And Grass Pollen Allergy Immunotherapy Tablets - Business Wire 02.22.13 | 08:02 am
- Merck And Samsung Bioepis Enter Biosimilars Development And Commercialization Agreement - Business Wire 02.20.13 | 07:02 am
Partner Headlines for MRK
- Companies slide $181B through tax loopholes - MSN Money 04.19.13 | 10:04 am
- Revive leadership in pharma R&D - Financial Times 04.17.13 | 08:04 pm
- Market Close Report: NASDAQ Composite index closes at 3,297.25 up 59.39 points - NASDAQ 04.10.13 | 08:04 pm
- Market Close Report: NASDAQ Composite index closes at 3,218.60 down -36.26 points - NASDAQ 04.03.13 | 08:04 pm
- 10 Sharp Healthcare Dogs Diagnose 7.4% To 62.1% Gains In March - Seeking Alpha 04.01.13 | 09:04 am
- New foot-and-mouth vaccine developed - Financial Times 03.27.13 | 11:03 pm
- 'Pay For Delay' Case Could Change Generic Drug Rules - Investor's Business Daily 03.26.13 | 04:03 pm
- Common Sense Says Time For Quality, Dividends And Premiums - Seeking Alpha 03.23.13 | 06:03 am
- Top 9 March Healthcare Dogs Mark 3.4% To 28.7% Gains - Seeking Alpha 03.23.13 | 04:03 am
- Looking For Bargains And Safety - Seeking Alpha 03.17.13 | 09:03 am
